Summary & Overview

CPT 0529U: Genomic Risk Assessment for Venous Thromboembolism

CPT code 0529U identifies a Proprietary Laboratory Analyses test — the Lifetime Genomics Risk Assessment, VTE, developed by GenomicMD Inc. The assay performs genome‑wide single‑nucleotide polymorphism analysis with focused evaluation of the F2 and F5 genes, including the Leiden variant, to estimate an individual’s genetic risk for venous thromboembolism. As a PLA code, 0529U applies only to this single manufacturer‑specific test, which has implications for coding consistency, billing transparency, and payer coverage decisions nationally.

Key payers in scope include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise summary of clinical purpose and service context, payer coverage considerations, and typical service and site‑of‑service information relevant to billing and coding teams. The publication outlines benchmarks and policy updates where available, clarifies the test’s clinical role in VTE risk assessment, and highlights administrative considerations tied to PLA coding. Data not available in the input is noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicare0529UCPTProprietary Laboratory Analysesgenetic testingvenous thromboembolismgenomic risk assessmentmolecular diagnosticsF5 LeidenF2 mutation

Billing Code Overview

CPT code 0529U is a Proprietary Laboratory Analyses (PLA) code that applies only to a single, unique laboratory test. Report 0529U only for the Lifetime Genomics Risk Assessment, VTE, from GenomicMD Inc. The test analyzes genome‑wide single‑nucleotide polymorphisms and includes targeted analysis of the F2 and F5 genes, including the Leiden variant, to determine an individual’s genetic risk of venous thromboembolism (VTE).

Service type: Genetic risk assessment using genome‑wide SNP analysis with targeted gene variant evaluation

Typical site of service: Clinical laboratory or specialized molecular diagnostics laboratory

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult with a personal or family history suggestive of inherited thrombophilia or a patient being evaluated for lifetime risk of venous thromboembolism (VTE). A primary care physician, hematologist, or genetic counselor orders the test 0529U (Lifetime Genomics Risk Assessment, VTE, GenomicMD Inc.) to assess genome-wide single-nucleotide polymorphisms and specific variants in the F2 and F5 genes including the Leiden variant. The clinical workflow: the provider documents indication and obtains informed consent for genetic testing; a blood or saliva specimen is collected in an outpatient clinic, phlebotomy lab, or genetic testing facility; the specimen is shipped to the performing laboratory; the laboratory performs genotyping and proprietary analysis; results are reported to the ordering provider with an interpretation of genetic risk; the provider integrates results into lifetime risk assessment, counseling, and management planning. Typical sites of service include outpatient physician offices, ambulatory phlebotomy centers, genetic counseling clinics, and commercial laboratory locations.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	Use when the laboratory or professional service requires substantially greater effort or resources than usual for test interpretation or reporting, and documentation supports unusual complexity.

Taxonomy Code	Specialty	Notes
2080P0400X	Clinical Molecular Genetics Laboratory	Laboratories performing high-complexity molecular diagnostics and PLA testing.
207K00000X	Hematology	Hematologists frequently order thrombophilia and VTE genetic risk testing.
2085R0201X	Clinical Laboratory	Commercial clinical laboratories that perform genetic testing and report PLA codes.
2084P0800X	Medical Genetics	Medical geneticists and genetic counselors interpret results and provide counseling.
207L00000X	Internal Medicine	Primary care physicians who order risk assessment testing for preventive care.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`I82.90`	Acute embolism and thrombosis of unspecified vein, unspecified site	Acute VTE event prompting assessment of genetic risk for recurrence.
`I82.403`	Acute embolism and thrombosis of deep veins of unspecified lower extremity, bilateral	Deep vein thrombosis presentation where genetic predisposition evaluation may be considered.
`Z15.01`	Genetic susceptibility to malignant neoplasm of breast	Example of genetic susceptibility coding conventions; not directly VTE but demonstrates hereditary risk coding patterns.
`Z13.79`	Encounter for screening for other specified genetic and chromosomal anomalies	Use for screening encounters when ordering lifetime genomic risk assessments.
`Z83.71`	Family history of pulmonary embolism and deep vein thrombosis	Family history that supports ordering `0529U` to assess inherited risk for VTE.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`81002`	Urinalysis, non-automated, without microscopy	Often performed in pre-test workup or general lab panels but not directly related to genetic analysis.
`36415`	Collection of venous blood by venipuncture	Commonly billed for specimen collection associated with `0529U` when blood is the specimen type.
`99000`	Handling and/or conveyance of specimens for transfer from referring facility to performing laboratory	Used when specimens are shipped to the performing laboratory for proprietary testing.
`81479`	Unlisted molecular pathology procedure	May be used historically if proprietary PLA code were unavailable; now replaced by specific PLA `0529U` for this test.
`99401`	Preventive medicine counseling, individual, approximately 15 minutes	Genetic counseling or risk discussion visit code that may accompany test ordering and result disclosure.